Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -194.19% | -190.40% | -25.74% | 14.16% | -3.84% |
| Total Depreciation and Amortization | 92.42% | 0.00% | 0.00% | -95.85% | 32.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15,320.60% | 5,693.77% | 0.61% | -75.40% | -56.69% |
| Change in Net Operating Assets | 83.77% | -290.41% | 120.62% | -114.22% | 144.53% |
| Cash from Operations | -6.12% | -55.29% | -18.90% | -10.71% | 35.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 736.14% | -1,732.18% | -85.19% | -0.82% | 43.28% |
| Cash from Investing | 735.74% | -1,732.18% | -85.19% | -0.26% | 43.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 19,936,800.00% | 181,900.00% | -- | -95.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 72,282.84% | 181,900.00% | 9,111.94% | -95.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 348.84% | 1,075.71% | -116.77% | 135.73% | -110.77% |